Successful desensitization to high-dose methotrexate after systemic anaphylaxis

Annals of Allergy, Asthma and Immunology

Volumn 90, Issue 1, 2003, Pages 87-89

  Davis, Kepler A ^a,b   Williams, Patrick ^a   Walker, John C ^a  

^a MADIGAN ARMY MEDICAL CENTER   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BICARBONATE; CETIRIZINE; CISPLATIN; DOXORUBICIN; FOLINIC ACID; GRANISETRON; HYDROXYZINE; IFOSFAMIDE; LORAZEPAM; METHOTREXATE; MONTELUKAST; PREDNISONE; RANITIDINE; TRYPTASE; FOLIC ACID ANTAGONIST;

ADULT; ANAPHYLAXIS; ARTICLE; BLOOD ANALYSIS; BREATHING DISORDER; CANCER ADJUVANT THERAPY; CASE REPORT; CLINICAL FEATURE; COUGHING; DESENSITIZATION; DRUG INFUSION; ENZYME BLOOD LEVEL; FACE EDEMA; HUMAN; HYPERSENSITIVITY REACTION; HYPOXEMIA; INTENSIVE CARE UNIT; KNEE AMPUTATION; LABORATORY TEST; MALE; MAST CELL DEGRANULATION; OSTEOSARCOMA; PARESTHESIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT; SKIN TEST; SNEEZING; THORAX DISEASE; TREATMENT OUTCOME; URTICARIA; BONE TUMOR; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE;

ADULT; ANAPHYLAXIS; BONE NEOPLASMS; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID ANTAGONISTS; HUMANS; MALE; METHOTREXATE; OSTEOSARCOMA;

EID: 0037267096     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63619-8     Document Type: Article

References (13)

1. Goldberg NH, Romolo JL, Austin EH, et al. Anaphylactoid type reaction in two patients receiving high dose intravenous methotrexate. Cancer 1978;41:52-55.
2. Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Intern Med 1981;94:66-72.
3. Alkins SA, Byrd JC, Morgan SK, et al. Anaphylactoid reactions to methotrexate. Cancer 1996;77:2123-2126.
4. Recker DP, Minor JR, Miller FW. Successful prevention of an anaphylactoid reaction to high-dose methotrexate. DICP 1989;23:1032.
5. Gluck-Kuyt I, Irwin LE. Anaphylactic reaction to high-dose methotrexate. Cancer Treat Rep 1979;63:797-798.
6. Cohn JR, Cohn JB, Fellin F, Cantor R. Systemic anaphylaxis from low dose methotrexate. Ann Allergy 1993;70:384-385.
7. Klimo P, Ibrahim E. Anaphylactic reaction to methotrexate used in high doses as an adjuvant treatment of osteogenic sarcoma. Cancer Treat Rep 1981;65:725.
8. Vega A, Cabanas R, Contreras J, et al. Anaphylaxis to methotrexate: a possible IgE-mediated mechanism. J Allergy Clin Immunol 1994;94:268-270.
9. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997;350:911-917.
10. Saeter G, Wiebe T, Wiklund T, et al. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl 1999;285:74-82.
11. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-959.
12. Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Cin Immunol 1991;87:867-871.
13. Da Costa M, Isacoff W, Rothenberg SP, Iqbal MP. Proteinmethotrexate-IgG complexes in the serum of patients receiving high-dose antifolate therapy. Cancer 1980;46:471-474.